FIELD: medicine.
SUBSTANCE: invention relates to a compound selected from the group consisting of
and pharmaceutically acceptable salts thereof. Invention also relates to pharmaceutical compositions, to a method of treating an EZH2-mediated disorder, to the use of a compound for the manufacture of a medicament.
EFFECT: technical result: obtaining novel compounds having the properties of inhibitors of EZH2 activity.
16 cl, 8 dwg, 9 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
| SALT FORM OF HUMAN HISTONE METHYLTRANSERASE EZH2 INHIBITOR | 2013 |
|
RU2658911C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| CRYSTAL FORMS OF TRIAZOLOPYRIMIDINE COMPOUND | 2017 |
|
RU2754856C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
| APPLICATION OF AN EZH2 INHIBITOR IN COMBINATION WITH A BTK INHIBITOR IN PRODUCTION OF A MEDICINAL PRODUCT FOR TREATING A TUMOUR | 2018 |
|
RU2762893C2 |
| IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | 2020 |
|
RU2785124C1 |
